Provided by Tiger Trade Technology Pte. Ltd.

Larimar Therapeutics, Inc.

4.68
+0.18004.00%
Post-market: 4.66-0.0200-0.43%19:29 EDT
Volume:1.84M
Turnover:8.64M
Market Cap:486.72M
PE:-2.06
High:4.82
Open:4.58
Low:4.58
Close:4.50
52wk High:6.42
52wk Low:1.61
Shares:104.00M
Float Shares:73.66M
Volume Ratio:0.95
T/O Rate:2.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2711
EPS(LYR):-2.2711
ROE:-132.59%
ROA:-62.31%
PB:6.23
PE(LYR):-2.06

Loading ...

Nomlabofusp’s Manageable Risk, Strong Efficacy Signals, and Significant FA Market Upside Underpin Buy Rating on LRMR

TIPRANKS
·
Yesterday

Larimar Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 23

Larimar Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview

Reuters
·
Mar 20

Citi Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

TIPRANKS
·
Mar 20

Larimar Therapeutics Q4 net loss rises more than doubled to USD 62.5 million as R&D expenses jump more than doubled to USD 59.4 million

Reuters
·
Mar 19

BRIEF-Larimar Therapeutics Q4 Net Income USD -62.498 Million

Reuters
·
Mar 19

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

THOMSON REUTERS
·
Mar 19

Larimar Therapeutics Inc - Bla Submission Planned for June 2026; U.S. Launch Targeted First-Half 2027

THOMSON REUTERS
·
Mar 19

Larimar Therapeutics Q4 EPS USD -0.73

THOMSON REUTERS
·
Mar 19

Larimar Therapeutics Q4 Operating Expenses USD 64.018 Million

THOMSON REUTERS
·
Mar 19

Larimar Therapeutics Inc - Topline Open Label Study Data Expected in Q2 2026

THOMSON REUTERS
·
Mar 19

James E. Flynn, Director, Acquires Larimar Therapeutics Common Shares

Reuters
·
Mar 03

Larimar Therapeutics Director Jeffrey W. Sherman Acquires Common Shares

Reuters
·
Mar 03

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Larimar Therapeutics (LRMR)

TIPRANKS
·
Feb 28

Top Premarket Decliners

MT Newswires Live
·
Feb 26

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

THOMSON REUTERS
·
Feb 26

Larimar Therapeutics Inc - Prices Upsized Public Offering at $5.00 per Share

THOMSON REUTERS
·
Feb 26

BUZZ-Larimar Therapeutics slips after $75 mln stock offering commenced

Reuters
·
Feb 26

Press Release: Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Dow Jones
·
Feb 26

Laminar Therapeutics Stock Is Popping Today: What's Going On?

Benzinga_recent_news
·
Feb 26